Tak-003

BIOLOGICAL2 trials

Sponsors

Takeda, Fundación Vacunar

Conditions

Dengue FeverDengue Vaccines

Phase 3

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

CompletedNCT03423173

TakedaDengue Fever

Start: 2018-02-12End: 2019-01-14Updated: 2020-10-20

Unknown Phase

Retrospective Analysis of the Second Year of Safety Surveillance of the Qdenga® (TAK-003) Vaccine in Private Vaccination Centers, Including a Sub-analysis of Safety in Adults Over 60 Years of Age

Active, not recruitingNCT07812142

Fundación VacunarDengue Vaccines

Start: 2024-11-02End: 2026-12-01Updated: 2026-09-10

Related Papers

Beyond neutralization: A comprehensive framework for evaluating humoral immunity induced by a live-attenuated tetravalent dengue vaccine.

2026-07-21

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine

Expert Review of Vaccines2025-03-184 citations

Consistency of immunogenicity in three consecutive lots of a tetravalent dengue vaccine candidate (TAK-003): A randomized placebo-controlled trial in US adults

Vaccine2023-10-2412 citations

An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life

Human Vaccines & Immunotherapeutics2023-08-0132 citations